ArticleConsortium psychiatricum2025
Generalized Bullous Fixed Drug Eruption Induced by Chlordiazepoxide: A Case Report of a Potentially Lethal Adverse Effect.
Article in Consortium psychiatricum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Etoricoxib-Induced Fixed Erythema.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFixed drug eruption is a type of adverse drug reaction affecting the skin, marked by recurrent rashes that appear at the same site each time a particular drug is taken. Generalized bullous fixed drug eruption (GBFDE) is a severe form of FDE characterized by vesicles or bullae and involvement of a significant portion of the body surface area. To date, no association between GBFDE and chlordiazepoxide has been reported in the literature. CASE REPORT: The authors present the case of a 40-year-old male inpatient in the psychiatry department of a tertiary care hospital in Assam, India. The patient was admitted in an alcohol withdrawal state and was initially prescribed chlordiazepoxide at a dose of 60 mg/day. He developed GBFDE within a day of chlordiazepoxide administration. The drug was discontinued, and he was treated with oral and topical corticosteroids instead, resulting in a significant improvement.
conclusionChlordiazepoxide is a rare but potential trigger of GBFDE. Clinicians should closely monitor patients on chlordiazepoxide for possible signs of GBFDE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.